1 min read
Add as a preferred source on Google

XTL Biopharmaceuticals Posts $0.00 GAAP EPS for First Half

Cash and cash equivalents were approximately $1.80 million at June 30, 2026, up from approximately $0.08 million on Dec. 31, 2025.

Two glass vessels hold contrasting amounts of clear liquid / TokenPost.ai
Two glass vessels hold contrasting amounts of clear liquid / TokenPost.ai

XTL Biopharmaceuticals Ltd. posted first-half GAAP earnings per share of $0.00.

Cash and cash equivalents totaled approximately $1.80 million on June 30, 2026, compared with approximately $0.08 million on Dec. 31, 2025.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…